94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
BRIEF RESEARCH REPORT article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1546607
Clinicopathological Analysis of 13 Patients with Embryonal Rhabdomyosarcoma of the Female Reproductive System in the Chinese population
Provisionally accepted- West China Second University Hospital, Sichuan University, Chengdu, China
Objective: Examine clinicopathological traits and differential diagnosis of ERMS in female reproductive system. Methods: Retrospectively assess 13 patients' data (Jan 2018 -Jun 2024, West China Second Univsity Hospital), covering clinical, histological, immunohistochemical aspects and literature review. Results: Age 2 months -67 years (median 21), sites in cervix (5), ovaries (3), uterus (2). Non-specific symptoms. Lesions with grape-like etc. morphologies. Immunohistochemistry: the tumor cells expressed Myogenin (11/13), Desmin (13/13), MyoD1 (12/13) and Myoglobin (5/9). . 4/5 had DICER1 mutations. According to the Children's Oncology Group Soft Tissue Sarcoma (COG-STS) risk classification，11 low risk, 2 high risk. Treatments: 8 surgery + chemotherapy, 2 surgery + chemotherapy + radiotherapy, 2 surgery only. 4 died, 8 survived, 1 lost follow up. Follow-up 2 -41 months (median 20).Discussion: ERMS is rare, diagnosed by histology and immunohistochemistry, DICER1 mutation may assist. Treatment is surgery + chemo ± radiotherapy, efficacy related to multiple factors. When ERMS is diagnosed, it is mostly in the early stage, and the treatment method is mostly surgery plus chemotherapy with or without radiotherapy. However, the treatment effect is related to factors such as staging, Intergroup Rhabdomyosarcoma Study (IRS) clinical grouping, COG-STS risk, patient age, and TP53 mutation.There is no clear guideline for the treatment of adult patients.
Keywords: Embryonal rhabdomyosarcoma, DIcer1, female reproductive system, Clinicopathology, Immunohistochemistry
Received: 17 Dec 2024; Accepted: 17 Feb 2025.
Copyright: © 2025 Bai, Han, Sun, Zou and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Juan Zou, West China Second University Hospital, Sichuan University, Chengdu, China
Yali Chen, West China Second University Hospital, Sichuan University, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.